GENESIS Pharma
Alexios Giotis has extensive experience in information systems, technology management, and software development. Currently serving as the Business Information Systems & Technology Manager at Genesis Pharma since October 2021, Alexios is responsible for the operation of information systems and infrastructure. Previously, as CEO and Co-Founder of Apscale Software Services S.A. from February 2021 to October 2021, Alexios established a software development firm delivering critical solutions for various sectors. During a long tenure at i-docs from January 2003 to February 2021, Alexios held several leadership roles, including Chief Technology Officer, where responsibilities included overseeing technical aspects and product development. Early career experience as a Research Engineer at NTUA focused on advanced computational techniques. Alexios holds a Dr. Engineer degree and an MSc in Mechanical Engineering from the National Technical University of Athens.
This person is not in any teams
GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative pharmaceutical products for severe and rare diseases in Central and Eastern Europe. Founded in 1997 in Greece, GENESIS Pharma S.A. was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. In 1999, business activities were expanded in Cyprus through the creation of GENESIS Pharma (Cyprus) Ltd, and later on, in markets of Southeast Europe. GENESIS Pharma (Cyprus) Ltd, an affiliate (sister) company, now operates in Central and Eastern Europe, through its subsidiaries in Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia, Slovenia (EU) as well as North Macedonia and Serbia (Non-EU). GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with leading international pharma companies committed to cutting-edge R&D as well as biopharma companies with disruptive innovations for the development of targeted, specialized treatments for orphan diseases. For more information, please visit www.genesispharmagroup.com and www.genesispharma.com